Here's one of the reasons for DYAX' spike; Please note that IMC-1121B is the FIRST total human anti-angiogenesis monoclonal antibody (developed via DYAX) and is being studied on multiple cancers; The favorable LIlly study on gastric ca. is linked below:
That is great news. It will be an interesting earnings call coming up. I am interested in cash on hand and burn rate. Last time they went the route of a loan, and didn't dilute shares. They may also cross the line to create a positive earnings.
It will be telling how they position the next round of funding and what the terms are.
What is the best case scenario for Lilly, in terms of money to DYAX?